Table 6.
Selected clinical trials of HIV prophylactic vaccines.
| Clinical trial identifier | Status | Phase | Vaccine approach | Alternative study ID | Vaccine components | Comment/references |
|---|---|---|---|---|---|---|
| NCT00002441 | Complete | III | Subunit priming and boosting | AIDSVAX B/B, VAX 004 | MN rgp120/HIV-1 and GNE8 rgp120/HIV-1 | No protection; Flynn et al., 2005 |
| NCT00006327 | Complete | III | Subunit priming and boosting | AIDSVAX B/E, VAX 003 | MN rgp120/HIV-1 and A244 rgp120/HIV-1 | No protection; Pitisuttithum et al., 2006 |
| NCT00223080 | Active | III | Vector priming, subunit boosting | RV-144 | ALVAC-HIV vCP1521 + AIDSVAX | 31.2% efficacy; Rerks-Ngarm et al., 2009 |
| NCT00095576 | Terminated | II | Vector priming and boosting | STEP study | Trivalent MRKAd5 HIV-1 gag/pol/nef | No protection; Buchbinder et al., 2008 |
| NCT00413725 | Suspended | II | Vector priming and boosting | Phambili study | MRKAd5 HIV-1 gag/pol/nef | No protection; Gray et al., 2011 |
| NCT00865566 | Recruiting | II | DNA priming, vector boosting | HVTN 505 | VRC-HIVDNA016-00-VP (DNA) + VRC-HIVADV014-00-VP (rAd5) | – |
| NCT00820846 | Active | II | DNA priming, vector boosting | HVTN 205 | pGA2/JS7 DNA + MVA/HIV clade B gag-pol-env | – |
| NCT01418235 | Recruiting | I | DNA/vector/subunit | HVTN 086/SAAVI 103 | DNA-C2 + MVA-C + gp140 in MF59 | – |
| NCT00062530 | Not yet recruiting | I | Recombinant bacteria | P01AI47490 | Oral recombinant Salmonella typhi HIV-1 gp120 | – |
| NCT01441193 | Recruiting | I | Subunit priming and boosting | ISS P-002 | HIV-1 Tat; delta-V2 Env | – |
| NCT01095224 | Recruiting | I | Vector priming and boosting | HVTN 083 | rAd35 Env A+rAd5 Env A or rAd5 Env B | – |
More information about the individual trials can be found using the NCT number and the following databases: www.aidsinfo.nih.gov/clinical-trials; www.clinicaltrials.gov; http://www.avac.org.